Article

A first-in-human clinical study of an intranasal spray of a cocktail containing two synergetic antibodies neutralizes Omicron BA.4/5

2023-03-20

Abstract excerpt

Neutralizing monoclonal antibodies (NAbs) with prophylactic and therapeutic efficacy have demonstrated fundamental importance in the control of SARS-CoV-2 transmission. However, their wide application has been largely limited by high cost and inconvenience in administration. Here, we developed an intranasal spray containing two synergetic human NAbs that could broadly neutralize the emerging Omicron variants in vi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 024942fd-1af3-56c1-a16e-6d78c6f44b70
DOI: 10.1101/2023.03.17.23287398

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A first-in-human clinical study of an intranasal spray of a cocktail containing two synergetic antibodies neutralizes Omicron BA.4/5DOI 10.1101/2023.03.17.23287398Read

A cocktail containing two synergetic antibodies broadly neutralizes SARS-CoV-2 and its variants including Omicron BA.1 and BA.2Semantic proximity Read

The Real-World Effectiveness of an Intranasal Spray A8G6 Antibody Cocktail in the Post-Exposure Prophylaxis of COVID-19Semantic proximity Read

The real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19Semantic proximity Read

A randomized, placebo-controlled trial of a nasal spray solution containing broadly potent neutralizing antibodies against SARS-CoV-2 variants in healthy volunteersSemantic proximity Read

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of ConcernSemantic proximity Read

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variantsSemantic proximity Read

ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernSemantic proximity Read

19n01, a Broadly Neutralizing Antibody Against Omicron BA.1, BA.2, BA.4/5, and Other SARS-CoV-2 Variants of ConcernSemantic proximity Read

Intranasal inhibitor broadly blocks SARS-CoV-2 including recent highly immunoevasive Omicron subvariantsSemantic proximity Read

Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal AntibodiesSemantic proximity Read

Robust SARS-CoV-2 Infection in Nasal Turbinate Despite Systemic Neutralizing AntibodySemantic proximity Read

Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K VariantsSemantic proximity Read